A computerized tablet system for evaluating treatment of essential tremor by magnetic resonance guided focused ultrasound
© The Author(s). 2017
Received: 5 October 2016
Accepted: 2 April 2017
Published: 17 April 2017
Transcranial magnetic resonance guided focused ultrasound is an emerging technology under evaluation for treatment of essential tremor, a prevalent movement disorder. A qualitative evaluation is performed by a clinician periodically during the procedure to maximize treatment effects and minimize adverse effects. The present work demonstrates a magnetic resonance-compatible method to enable more precise, quantitative measurement of tremor severity.
Tremor severity was measured in 12 patients pre-, post-, and intra-operatively, using a magnetic resonance-compatible tablet and a computerized adaptation of drawing tasks from the widely-used Fahn-Tolosa-Marin Tremor Rating Scale. Tremor metrics based on spectral analysis were calculated for each drawing and compared using Wilcoxon signed rank tests.
Tremor metrics in the dominant (treated) hand were significantly and consistently lower post-operatively compared to pre-operatively, but there was no significant difference in the non-dominant (untreated) hand, as expected. Intra-operative metrics were intermediate between pre- and post-operative metrics.
Use of the tablet for quantitative tremor measurement was demonstrated pre-, post-, and intra-operatively during treatment of essential tremor, complementing standard qualitative assessment. With additional work, the system has potential to add objectivity to clinical trials and to aid treatment decision-making by providing a metric for optimization during the procedure, which may eventually lead to more optimal treatment. Enhancements and further studies are suggested, and extensions to fMRI studies of essential tremor and Parkinson’s disease are also likely.
KeywordsEssential tremor Movement disorders Magnetic resonance imaging Magnetic resonance guided focused ultrasound Tablet Drawing
Transcranial magnetic resonance guided focused ultrasound (MRgFUS) is an emerging technology that promises revolutionary new treatments of the brain without open neurosurgery . In the past two decades, advances in ultrasound transducers and computation have enabled delivery of focused energy through the intact skull (“sonication”), while advances in magnetic resonance imaging (MRI) techniques have enabled surgical planning with millimetre spatial resolution, as well as accurate, non-invasive temperature mapping for real-time monitoring during therapy. Of the various brain disorders amenable to treatment by transcranial MRgFUS, there has been much early interest in ablation treatments for essential tremor (ET) . ET is a common movement disorder characterized by persistent kinetic or postural tremor of the upper extremities, with a prevalence of 0.9% overall and 4.6% for individuals over 65 years of age . The affliction is progressive and can lead to significant disability and functional impairment, but at least 30% of ET patients do not respond to established medications , while a further 30% of ET patients stop taking their medication . In such patients, ablative transcranial MRgFUS can be used to perform a thalamotomy of the ventral intermediate nucleus, the key cerebellar-motor relay where neuronal oscillations have been linked to ET. Initial clinical trials are demonstrating the safety and efficacy of the approach [4, 5].
In addition to preoperative and postoperative imaging sessions and neurological examination, the typical MRgFUS treatment for such patients is conducted over several hours . The target treatment volume for ablation is identified by anatomical MRI, and multiple sonications are then performed to heat the treatment volume under guidance by real-time MRI thermometry. The latter process is performed slowly and cautiously. First, the sonication temperature is raised to sublethal thresholds that have a temporary and reversible effect on neuronal activity, then ablation is performed if appropriate. Throughout treatment, the patient is examined repeatedly by a clinician for both therapeutic (reduced tremor) and adverse events. In particular, sensory or motor disturbances following sublethal sonications enable the clinician to improve targeting of the thermal lesion, to maximize tremor reduction and minimize permanent side effects, such as paresthesia of the fingers.
Although considerable effort has been directed towards optimizing the ultrasound and MRI technology for transcranial MRgFUS procedures, the behavioral testing of patients during treatment has not yet received the same level of attention. Testing typically involves qualitative evaluation of tremor using simple motor and drawing tasks like those from Parts A and B of the Fahn-Tolosa-Marin Clinical Rating Scale for Tremor , with emphasis on testing of the treated arm, and questioning the patient for their subjective report of sensorimotor side effects [4, 5, 7]. This testing can be time consuming as it usually requires a clinician to enter the MRI scanner room, moving the patient table out of the scanner, testing, repositioning the patient in the scanner, and clearing the room. Improvements could potentially be made by supplementing qualitative and subjective assessments by others that are more quantitative and objective. Computerized tests administered from the MRI console are particularly attractive. A digital record of treatment effects can be generated automatically by this means. Even more importantly, the quantitative results from computerized tests may provide more accurate assessment of treatment and side effects, and enable more time-efficient testing during sonications as well as between sonications. These improvements to accuracy and efficiency—potentially leading to enhanced patient outcomes and reduced treatment costs—are predicated on the ability to perform quantitative and computerized behavioral testing within the confines of an MRI system during MRgFUS.
Recently, an MRI-compatible computerized behavioral testing system has been developed  that holds promise for transcranial MRgFUS applications. The system, which includes a touch-sensitive tablet similar in form to a digitizing graphics tablet, was originally developed with the intention of expanding functional magnetic resonance imaging (fMRI) capabilities to record brain activity associated with behavioral tasks involving writing and drawing, particularly “paper and pencil” tests used clinically for neuropsychological evaluation of patients. The present work involves initial evaluation of the tablet system applied to transcranial MRgFUS for treatment of ET. The specific goals are: 1) to adapt existing, validated tests for use with the tablet system to assess ET; 2) to establish initial metrics to quantify performance on these tests; 3) to apply the tablet system during MRgFUS treatment of ET; and 4) to demonstrate treatment effects using the tablet system metrics. The quality and ramifications of the resulting data are subsequently discussed, as well as modifications that could be made to the tablet system to enhance its utility for MRgFUS applications in the future.
Twelve ET patients (64–85 y.o.; 4 females; 4 left handed) were recruited from the participants of clinical trials of MRgFUS for unilateral thalamotomy (NCT01827904) , at the Sunnybrook Health Sciences Centre location. The patients gave separate informed consent to participate in the present pilot study using the tablet, with approval of the local Research Ethics Board. For the pre-operative test, one to two weeks prior to the MRgFUS procedure, participants sat in a chair in front of a computer with the tablet resting in their lap. They first familiarized themselves with the use of the tablet and stylus by writing their name with their unsupported dominant hand (to be treated), before continuing on to spiral and line drawing tasks (described below). They then repeated the same drawing tasks with the non-dominant hand, to serve as a baseline that was not expected to change after the unilateral procedure. As this was a proof-of-concept demonstration, logistical considerations, e.g. length of treatment time and occasional technical issues related to the MRgFUS equipment, dictated that three participants were not tested intra-operatively, but they did complete the pre- and post-operative tests. A further three participants completed only the pre-operative test, but neither intra-operative nor post-operative tests. (Two of these participants ultimately did not meet the inclusion criteria for the MRgFUS trial, and one participant was not tested because of scheduling issues.) Therefore, six of the 12 participants completed the drawing tasks intra-operatively between sonication phases, but only with the dominant hand (contralateral to the ablation). These participants were supine with the tablet supported by cushions on their abdomen, and they wore modified prism glasses (Scan Sound, Inc., Deerfield, FL) to view the computer display on a projection screen located outside the MRI bore. Finally, nine of the 12 participants were tested post-operatively, several minutes after exiting the MRI room and removing the stereotactic frame, following the same procedure as the pre-operative test.
Statistics of tremor metrics
Drawing A: Big Spiral
Drawing B: Small Spiral
Drawing C: Lines
p = 0.016 *
p = 0.008 *
p = 0.008 *
p = 0.945
p = 0.547
p = 0.945
This study demonstrates an MRI-compatible setup for quantitative tremor measurement that can be used pre-, post-, and intra-operatively during MRgFUS thalamotomy procedures, for treatment monitoring and to inform neurosurgical decision-making. Drawing tasks from the widely-used Fahn-Tolosa-Marin Tremor Rating Scale were adapted as faithfully as possible, and a validated quantitative tremor metric  was calculated. The system performed as expected, with the results reflecting a significant decrease in tremor of the dominant (treated) hand, but not the non-dominant (untreated) hand. The results are highly suggestive of the MRgFUS treatment’s short-term efficacy. However, to be clear, the present pilot study was not designed to examine the treatment’s value—there was no control group, for example. Instead, we showed the utility of the MRI-compatible tablet system for tremor quantification during various stages of MRgFUS treatment.
A major feature of the tablet system is that it enables quantitative tremor measurement during the procedure in the MRI suite. Currently, the MRgFUS procedure can be quite lengthy, depending largely on the difficulty of localization and occasionally due to technical issues, so our proof-of-concept study was assigned a low priority, and for a few patients the decision was made to omit the tablet experiment. No attempt at hypothesis testing was planned or attempted with the six participants who had varying numbers of intra-operative tests with the tablet. Nevertheless, intra-operative metrics tended to be intermediate between pre- and post-operative metrics in the dominant (treated) hand. The intra-operative tremor values were closer to the post-operative values, perhaps because the intra-operative tests occurred later in the procedure, during the longer cool-down periods between high-energy ablative sonications. On the other hand, the intra-operative tests were performed while lying down, and this difference in posture means these tests may not be directly comparable to the pre- and post-operative tests. Additional testing would be required to explore how the metrics differ when lying down versus sitting. However, such a difference would not preclude use of this test on the scanner table, because in this context the test’s purpose is to quantify change from a baseline acquired early in the procedure. Further testing with more deliberate intra-operative testing is suggested to examine how test performance changes during the MRgFUS procedure, and how such changes relate to clinical outcomes. This knowledge could potentially aid treatment decision-making by establishing treatment optimization thresholds based on quantitative tremor measurements (e.g. terminating treatment after reaching X% tremor reduction, or after reaching some plateau). However, such a scheme should ideally be a joint optimization with yet-to-be determined measurements of adverse effects, which still occur at substantial levels in early ET MRgFUS trials .
After testing the three different drawing types, no strong conclusions can be made about their relative usefulness. The tremor metrics for all three drawings were fairly consistent: 7 of 8 participants showed a pre-post decrease in Drawing A, whereas 8 of 8 participants showed a decrease in Drawings B and C. However, some minor practical issues were observed when participants were tested with Drawing C. Some participants drew the straight lines with quick, “ballistic” movements, rather than deliberate and well-controlled strokes. They were asked to redo the test in extreme cases, but this issue may still be true to some degree. This type of motion is not the sort expected to generate the most tremor, and it shortens the sampling time, thus reducing the accuracy of the measurement. This may have contributed to the lower median tremor metrics for Drawing C in the non-dominant hand. It was also not obvious to users, without clear instructions, whether the lines should be drawn separately and in which direction. These issues are not evident with the spirals, and furthermore spirals have more literature validating their use with quantification [11–14]. The added time required to complete all three drawings rather than one or two is minimal, however. All three drawings should be performed for completeness, with additional direction given to ensure the consistency of the drawing technique in Drawing C.
Future practical enhancements of the testing setup include improved automation of stylus data censoring and selection, to enable quicker, interactive processing. Flexibility is important because, across participants, there was quite a lot of variability in start/end times and locations, speed, and severity of tremor, which made it challenging to select portions of drawings automatically where the participants were clearly on-task. Our MATLAB-based prototype interface (Fig. 2) was a step towards ensuring data quality, but it could be augmented to allow interactive selection of the various censorship options, the data for inclusion, and peak frequencies for tremor metric calculation. Another potentially useful enhancement is the inclusion of stylus pressure in the data analysis, which increases complexity but has been shown to reflect tremor severity . In the present work, we recorded pressure but did not use it in the absence of clear instructions or meaningful feedback to the participants. The drawing tasks could be augmented to change the size and/or color of the line or cursor when the participant moves out of a target range, analogous to the spiral guide lines in the X-Y plane. The subsequent data analysis could then act on the pressure data separately or in combination with the X-Y coordinates. Additionally, accelerometers and electromyography have been used to quantify tremor in research with drawing tasks as well as other action tasks and rest . With the commercial availability of MRI-compatible accelerometers and electromyographs, quantification of many of the other items of the Fahn-Tolosa-Marin Tremor Rating Scale is now possible. Finally, the patient’s sight lines in the current MRgFUS setup are highly constrained by the transducer array “helmet”, the attached membrane that bulges out over the eyes, and anterior elements of the stereotactic frame. A modified pair of prism glasses were used in the present work, mounted above the eyes with tape, to allow participants to see around these obstructions. For some participants the glasses were positioned only temporarily for the duration of each intra-operative test, to prevent any influence of the glasses on the ultrasound transmission due to contact with the membrane. An articulated mount will be constructed to make it easier and quicker to position the glasses.
With these refinements, MRI-compatible tablet-based tremor quantification during MRgFUS thalamotomy has potential to improve clinical trials by increasing their precision and objectivity. With additional work, this may eventually lead to improved patient outcomes both indirectly, through improved research quality, and directly, by providing a metric for optimization during the operation to maximize treatment effect, in concert with other tests aimed at minimizing adverse effects. Reduced costs may result both indirectly, through improved patient outcomes and reduced followup treatment, and directly, by saving time with automated testing that can be initiated without entering the MRI suite and repositioning the patient table, possibly even occurring during sonication. Alternatively, the time saved could be used to measure tremor more frequently for a finer grained appreciation of the change during the procedure, and it could be used to do more thorough testing for adverse effects. The apparatus may also be of use during fMRI of ET and other diseases with tremor such as Parkinson’s disease (PD), although this may require particularly effective head motion correction strategies when not using a stereotactic frame. It remains to be seen whether fMRI using the present drawing task would be of value in localization of the MRgFUS treatment volume. There is also increasing evidence that, like PD, ET is associated with a range of neurocognitive deficits , and the tablet can enable study of the neurological bases of these deficits, using standard paper-and-pencil neuropsychological tests during fMRI.
An MRI-compatible setup for quantitative tremor measurement was demonstrated that can be used pre-, post-, and intra-operatively during MRgFUS thalamotomy procedures, complementing standard qualitative assessment. After suggested enhancements and further testing, the system has potential to add objectivity to clinical trials and may lead to more optimal treatment. Extensions to fMRI studies of ET and PD are also likely.
Functional magnetic resonance imaging
Magnetic resonance-guided focused ultrasound
Magnetic resonance imaging
Special thanks to Ruby Endre for her support during data collection.
Funding was provided by the Natural Sciences and Engineering Research Council of Canada and the Canadian Cancer Society Research Institute.
Availability of data and materials
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
FT had a large role in the study design, did all the data collection and analysis, and did a large part of the interpretation and manuscript drafting. YH assisted in data collection and manuscript revision. MS contributed to the study design and assisted in data collection. TS contributed to interpretation and manuscript revision. KH contributed to the study design and revision of the manuscript. SG conceived of the study and did a large part of the interpretation and manuscript drafting. All authors approved the final manuscript.
FT, TS, and SG have invented intellectual property related to tablet technology. KH has invented intellectual property related to MRgFUS technology.
Consent for publication
Ethics approval and consent to participate
All participants gave written informed consent, with approval of the Sunnybrook Health Sciences Centre Research Ethics Board.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Lipsman N, Mainprize TG, Schwartz ML, Hynynen K, Lozano AM. Intracranial applications of magnetic resonance-guided focused ultrasound. Neurotherapeutics. 2014;11:593–605.View ArticlePubMedPubMed CentralGoogle Scholar
- Louis ED, Ferreira JJ. How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. Mov Disord. 2010;25(5):534–41.View ArticlePubMedGoogle Scholar
- Zesiewicz TA, Elble R, Louis ED, Hauser RA, Sullivan KL, Dewey Jr RB, Ondo WG, Gronseth GS, Weiner WJ. Practice parameter: therapies for essential tremor, report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2005;64:2008–20.
- Elias WJ, Huss D, Voss T, Loomba J, Khaled M, Zadicario E, Frysinger RC, Sperling SA, Wylie S, Monteith SJ, Druzgal J, Shah BB, Harrison M, Wintermark M. A pilot study of focused ultrasound thalamotomy for essential tremor. N Engl J Med. 2013;369:640–8.View ArticlePubMedGoogle Scholar
- Elias WJ, Lipsman N, Ondo WG, Ghanouni P, Kim YG, Lee W, Schwartz M, Hynynen K, Lozano AM, Shah BB, Huss D, Dallapiazza RF, Gwinn R, Witt J, Ro S, Eisenberg HM, Fishman PS, Gandhi D, Halpern CH, Chuang R, Butts Pauly K, Tierney TS, Hayes MT, Cosgrove GR, Yamaguchi T, Abe K, Taira T, Chang JW. A randomized trial of focused ultrasound thalamotomy for essential tremor. N Engl J Med. 2016;375:730–9.View ArticlePubMedGoogle Scholar
- Fahn S, Tolosa E, Marin C. Clinical rating scale for tremor. In: Jankovic J, Tolosa E, editors. Parkinson’s disease and movement disorders. 2nd ed. Baltimore: Williams & Wilkins; 1993. p. 271–80.Google Scholar
- Lipsman N, Schwartz ML, Huang Y, Lee L, Sankar T, Chapman M, Hynynen K, Lozano AM. MR-guided focused ultrasound thalamotomy for essential tremor: a proof-of-concept study. Lancet Neurol. 2013;12:462–8.View ArticlePubMedGoogle Scholar
- Tam F, Churchill NW, Strother SC, Graham SJ. A new tablet for writing and drawing during functional MRI. Hum Brain Mapp. 2011;32:240–8.View ArticlePubMedGoogle Scholar
- Elble R, Bain P, João Forjaz M, Haubenberger D, Testa C, Goetz CG, Leentjens AFG, Martinez-Martin P, Pavy-Le Traon A, Post B, Sampaio C, Stebbins GT, Weintraub D, Schrag A. Task force report: scales for screening and evaluating tremor. Mov Disord. 2013;28(13):1793–800.
- Stacy MA, Elble RJ, Ondo WG, Wu SC, Hulihan J. Assessment of interrater and intrarater reliability of the Fahn-Tolosa-Marin tremor rating scale in essential tremor. Mov Disord. 2007;22(6):833–8.View ArticlePubMedGoogle Scholar
- Elble RJ, Brilliant M, Leffler K, Higgins C. Quantification of essential tremor in writing and drawing. Mov Disord. 1996;11(1):70–8.View ArticlePubMedGoogle Scholar
- Haubenberger D, Kalowitz D, Nahab FB, Toro C, Ippolito D, Luckenbaugh DA, Wittevrongel MA, Hallet M. Validation of digital spiral analysis as outcome parameter for clinical trials in essential tremor. Mov Disord. 2011;26(11):2073–80.View ArticlePubMedPubMed CentralGoogle Scholar
- Elble RJ, Sinha R, Higgins C. Quantification of tremor with a digitizing tablet. J Neurosci Methods. 1990;32:193–8.View ArticlePubMedGoogle Scholar
- Pullman SL. Spiral analysis: a new technique for measuring tremor with a digitizing tablet. Mov Disord. 1998;13(S3):85–9.View ArticlePubMedGoogle Scholar
- Hess CW, Pullman SL. Tremor: clinical phenomenology and assessment techniques. Tremor Other Hyperkinet Mov. 2012;2. doi:10.7916/D8WM1C41.
- Jhunjhunwala K, Pal PK. The non-motor features of essential tremor: a primary disease feature or just a secondary phenomenon? Tremor Other Hyperkinet Mov 2014;4. doi:10.7916/D8D798MZ.